Teladoc and Pfizer Shares Drop Over 50%, But Have Strengths for Long-Term Growth
-
Teladoc Health (TDOC) and Pfizer (PFE) shares have dropped 50%+ recently but have great long-term potential.
-
Teladoc is delivering revenue and visit growth, improving profitability, and winning clients with whole person care offerings.
-
Pfizer's growth beyond COVID includes $20B projected from new products by 2030 and $25B from deals like Seagen.
-
Pfizer has an attractive valuation even excluding COVID products, plus a high dividend yield nearing 5.7%.
-
Both stocks could see a boost in an impending bull market, but more importantly have strengths to deliver over the long term.